XP-524 is a potent BET and EP300 inhibitor with strong in vivo antitumor activity; it prevents KRAS-induced tumorigenesis in vivo and extends survival in two aggressive PDAC transgenic mouse models; it also enhances self-peptide presentation and recruits tumor cells to cytotoxic T lymphocytes; XP-524 shows potential for the investigation of pancreatic ductal adenocarcinoma (PDAC).